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A facile approach to tryptophan derivatives for
the total synthesis of argyrin analogues†
Chou-Hsiung Chen,‡ Sivaneswary Genapathy,‡ Peter M. Fischer and Weng C. Chan*
A facile route has been established for the synthesis of indole-sub-
stituted (S)-tryptophans from corresponding indoles, which utilizes
a chiral auxiliary-facilitated Strecker amino acid synthesis strategy.
The chiral auxiliary reagents evaluated were (S)-methylbenzyl-
amine and related derivatives. To illustrate the robustness of
the method, eight optically pure (S)-tryptophan analogues were
synthesized, which were subsequently used for the convergent
synthesis of a potent antibacterial agent, argyrin A and its analogues.
Tryptophan and its derivatives are key biosynthetic precursors
in many nonribosomal peptide antibiotics. These peptidic
compounds typically display a wide spectrum of biological
activities. Specifically, the argyrins, a family of eight 24-
membered macrocyclic peptides isolated from the marine
myxobacterium Archangium gephyra,1,2 have been associated
with antibacterial,2–4 antiinflammatory2 and antiproteasomal5,6
activities. All biologically active members of the family contain
an unusual (S)-4-methoxy-tryptophan residue.1–6 Argyrin A and
B display potent antibacterial activity against the opportunistic
human pathogen Pseudomonas aeruginosa,1,2,7,8 which is the
result of functional inhibition of elongation factor G (EF-G).7,8
Utilizing the nomenclature recently introduced by Villar et al.,9
argyrin B7 appeared to engage in a compact binding mode with
EF-G, in which ‘peripheral atoms’ and ‘substituent atoms’ make
extensive contacts with EF-G. This binding mode reveals inti-
mate polar and nonpolar interactions between EF-G and the
4-methoxy-tryptophan side-chain (substituent atoms) of argyrin B.
While the (S)-4-methoxy-tryptophan residue in argyrin A
has been identified as crucial for its antiproteasomal activity
in human cancer cell lines,6 the structure–activity relation-
ships (SARs) of this residue that govern the peptide antibacter-
ial property remain unexplored. Therefore a variety of (S)-Trp
analogues were prepared in order to investigate the role of this
indolyl amino acid residue in antibacterial activity.
Current methods employed for the synthesis of enantio-
merically pure (S)-Trp analogues rely on either enzymatic or
chemical approaches. The enzymatic approach involves a final-
step resolution of the racemates using N-acylase enzyme,
which aﬀords a mixture of the desired product and the un-
processed (R)-N-acetyl-tryptophan.10 Chemical approaches in
the past have exploited various chiral auxiliaries to access
enantiomerically pure (S)-Trp analogues. For example, Ma
et al.11 utilize a Schöllkopf chiral auxiliary whilst Buelow et al.6
employ a DuanPhos ligand. We herein report our progress
towards the development of a flexible and operationally simple
synthetic route to a raft of (S)-Trp analogues. Our strategy
exploits a previously reported asymmetric Strecker synthesis of
aliphatic α-aminonitriles that employs chiral auxiliary reagents,
such as (S)-α-methylbenzylamine, which in turn delivers ali-
phatic (S)-amino acids.12 The new (S)-Trp analogues were then
used for the total chemical synthesis of argyrin A and related
analogues. In contrast to previously reported solution-based
fragment condensation approaches,10a,13 we also report for the
first time a robust Fmoc/tBu solid-phase peptide synthesis
(SPPS) strategy for the stepwise assembly of the octapeptide.
In our appraisal of the α-substituted benzylamine-facilitated
Strecker synthesis of new (S)-Trp analogues (Scheme 1), several
key challenges were addressed, including the stability of inter-
mediates, the availability of chiral auxiliary reagents that are
inexpensive and are tolerant to a wide range of substrates, and
the stereoselectivity of the condensation reaction.
Thus, a variety of commercially available indoles 1 were
subjected to Vilsmeier formylation to give indole-3-carb-
aldehydes 2, which were then homologated via a Wittig reac-
tion to aﬀord the 2-(indol-3-yl)acetaldehydes 3. In the latter
transformation, eﬃciency of the acid hydrolysis of the enol
ether intermediates was found to be dependent on the elec-
tronic nature of substituents in the indole ring. Regardless of
the position, indoles with an electron-donating substituent
(2e–h) were more labile to acid-mediated decomposition than
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their counterparts with an electron-withdrawing substituent
(2b–d) (Table 1). Moreover, the 2-(indol-3-yl)acetaldehydes
3e–h were typically found to be unstable on storage. Hence,
the two-step homologation reaction was carefully monitored by
TLC to avoid decomposition and the reaction products were
immediately subjected to Strecker condensation to yield the
α-aminonitriles 4.
For the crucial three-component Strecker condensation
reaction, we started our study by evaluating the eﬀectiveness of
the chiral auxiliary agent (R)-2-phenylglycinol 1014 in compari-
son to the standard reagent (S)-α-methylbenzylamine 11
(Fig. 1).12 Using 2-(indol-3-yl)acetaldehyde 3a as the model
substrate, initial condensation of 10 with the protonated alde-
hyde 3a generates an imine intermediate which in turn is
attacked by a cyanide anion to yield the α-aminonitrile 4a.12 As
anticipated, the nucleophilic nitrile addition occurs at the
more favourable, less shielded diastereotopic re-face to aﬀord
the (S,R)-diastereomer 4a as the predominant product. Simi-
larly, (S)-α-methylbenzylamine 11 gave the re-addition product,
a (S,S) variant of 4a. Both the chiral auxiliary agents 10 and 11
gave the products 4 with a favourable dr 2–3 : 1, which was
determined by RP-HPLC analysis; a dr in this range was also
observed for all indole variants (a–h) examined in this study.
For the next transformation step, initial attempts to hydro-
lyse the α-aminonitriles 4 directly to α-amino acids proved to
be diﬃcult. Typical acid- or base-catalysed hydrolytic methods
required concentrated acid or strong alkali at high tempera-
ture,15 which in our case resulted in an intractable mixture of
decomposition products. Hence, we opted for an indirect
route, by converting the α-aminonitriles 4 to α-amino amides 5
and 6, which was achieved by employing 30% aqueous H2O2–
DMSO–K2CO3.
16,17 The additive DMSO significantly acceler-
ated the reaction under mild basic conditions. In fact, the
H2O2-enabled oxidation of α-aminonitriles was highly eﬃcient
and gave exclusively the α-amino amide diastereomers 5 and 6
in good yields. At this stage, we found that the α-amino
amides 5 and 6 were readily and eﬃciently separated by pre-
parative silica gel flash-chromatography, to deliver the required
diastereomerically pure compounds 6. It is worth noting that,
when (S)-α-methylbenzylamine 11 was utilized, we were unable
to achieve reliable separation of the corresponding α-(methyl-
benzylamino) amides by column chromatography.
Since the S-isomer is the required enantiomer, compounds
6 were used for subsequent investigations. We next established
that an unmasking step, i.e. the debenzylation step, followed
by mild acid hydrolysis was the most robust procedure to
finally furnish the (S)-Trp analogues 8. It has been previously
Scheme 1 Synthesis of tryptophan analogues.
Table 1 Homologation of indole-3-aldehyde derivatives 2 followed by
hydrolysis to the 2-(1H-indol-3-yl)acetaldehydes 3





a H 0.4 2.5 69
b 5-Br 0.4 2 74
c 5-Cl 0.4 2 74
d 6-F 0.4 2 73
e 7-Et 0.4 1.5 65
f 5-Me 0.4 1.5 60
g 5-MeO 0.1 1.5 55
h 4-MeO 0.1 1.5 47
Fig. 1 The chiral auxiliaries amine reagents used in the Strecker syn-
thesis strategy.
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reported that the methyl group in the α-position could prevent
N-debenzylation under standard hydrogenolysis conditions.18
Although the use of the more active Pearlman’s catalyst
Pd(OH)2/C to remove the N-α-methylbenzyl group was con-
sidered, it poses a risk of reducing the indole system.19–21 To
avoid this, we employed catalytic phase transfer hydrogenolysis
to promote the N-debenzylation of compounds 6.22 Accord-
ingly, 10% Pd/C in the presence of excess ammonium formate
in MeOH,23 was used to aﬀord specifically 7a and 7d–h.
However, hydrogenolysis of the halogen-substituted com-
pounds 6b and 6c led to concomitant dehalogenation, resulting
in 7a as the only isolated product. Selective hydrogenolytic
debenzylation in the presence of bromo- and chloro-substituted
phenyls remain poorly explored. Li et al. reported the use
of chloride salt in the selective hydrogenolysis of O-benzyl
groups in the presence of aryl chloride.24 Unfortunately, using
similar conditions, we observed dehalogenation of our substrates
6b and 6c.
To overcome the above problem, we investigated the use of
an alternative chiral auxiliary reagent, 4-methoxy-α-methyl-
benzylamine (PMB) 12, to generate the α-amino amides 13 and
14. Various oxidative, reductive and acidolytic methods could
subsequently be used to remove the PMB group.25 Our initial
attempts of oxidative removal using CAN or DDQ26 were unsuc-
cessful. Gratifyingly, treatment of 13 and 14 with TFA under
reflux enabled eﬃcient acidolytic removal of PMB to yield 7b
and 7c, respectively (Scheme 2).
The unmasked α-amino amides 7a–h were subsequently
subjected to mild hydrolysis using 1 M aqueous HCl under
reflux condition for 5 h. This aﬀorded the α-amino acids 8 in
good-to-excellent yields (>80%). Since these new tryptophan
analogues are required for peptide synthesis, without further
purification, compounds 8 were Fmoc-protected using stan-
dard procedures to aﬀord 9. In addition to using 1H NMR to
establish purity, their absolute configuration was established.
Specifically, the observed [α]24D −29 and −23 for 9a and 9g,
respectively, are comparable to the values reported in the lit-
erature, [α]25D −29.5 (c 1, DMF)27 and −24.5 (c 1, MeOH).10b The
outlined synthetic routes therefore delivered a raft of enantio-
merically pure (S)-Fmoc-tryptophan analogues.
The Fmoc-protected amino acids 9 were then used for the
total chemical synthesis of argyrin A and analogues thereof.
This entailed stepwise assembly of the peptide sequence using
Fmoc/tBu solid-phase peptide synthesis (SPPS) followed by
acidolytic (TFA–CH2Cl2–H2O–iPr3SiH) release of the linear
Scheme 2 The acidolytic removal of N-PMB group.
Scheme 3 Fmoc/tBu solid-phase synthesis followed by macrocyclization to aﬀord argyrin A and its analogues.
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peptide and subsequent head-to-tail macrocyclization
(Scheme 3). In this context, the (S)-Fmoc-β-phenylseleno
cysteine 15 was used as a masked precursor for the dehydro-
alanine residue, and the thiazole dipeptide28 was N-Boc pro-
tected (16) (see ESI†). Thus, the synthesized linear peptides 18
were subjected to PyBOP-mediated macrocyclization to yield
19, followed by an oxidation–elimination reaction to aﬀord the
desired argyrin A 20h and related analogues 20a–g. The purity
of the cyclic peptides were established by 1H NMR and
reversed-phase HPLC.
The antibacterial activity of a selection of argyrin analogues
was evaluated against two Gram-negative bacteria, Pseudomo-
nas aeruginosa PAO1 and Proteus mirabilis Hauser 1885 (ESI
Table S1†). While the activity of argyrin A 20h against P. aerugi-
nosa PAO1 (MIC50 = 19.8 ± 1.6 µM) is comparable to a reported
value8 (Fig. 2), we were pleasantly surprised that the argyrin
analogue 20g, comprised of a (S)-5-methoxy-tryptophan
residue, showed MIC50 of 90–100 µM against both bacteria. In
contrast, the (S)-5-chloro- and (S)-5-methyl-tryptophan contain-
ing analogues 20c and 20f were essentially inactive. The experi-
mental complex structure between bacterial EF-G and argyrin
B shows a H-bond from Ser417 to the O of the 4-methoxy
group in the Trp residue.7 Preliminary inspection of the
complex structure suggests that either the H-bond is main-
tained but weaker due to an increased distance, or the 5-OMe
is capable of H-bond interaction with Tyr683. However, argyrin
analogues lacking a H-bond acceptor in a suitable position
(20c and 20f ) were inactive.
Conclusions
A facile approach for the synthesis of enantiomerically pure
(S)-tryptophan with halo-, methoxy- and alkyl-substitution has
been established using inexpensive (S)-methylbenzylamine-
based chiral auxiliary reagents. Using our range of new (S)-Trp
analogues, we have also discovered that the antimicrobial
activity of argyrin A, although dependent on the (S)-4-methoxy-
tryptophan residue, tolerates a (S)-5-methoxy-tryptophan
residue. We anticipate this will provide a useful platform for
the design and synthesis of more potent and species-specific
antibacterial agent.
Acknowledgements
We would like to acknowledge financial support from CS Bio
Company Inc., USA (to C.H.C.) and Vice-Chancellor’s Scholar-
ship for Research Excellence, University of Nottingham (to S.G.).
Notes and references
1 E. Selva, L. Gastaldo, G. S. Saddler, G. Toppo, P. Ferrari,
G. Carniti and B. P. Goldstein, J. Antibiot., 1996, 49, 145–149.
2 F. Sasse, H. Steinmetz, T. Schupp, F. Petersen,
K. Memmert, H. Hofmann, C. Heusser, V. Brinkmann,
P. von Matt, G. Hofle and H. Reichenbach, J. Antibiot.,
2002, 55, 543–551.
3 P. Ferrari, K. Vekey, M. Galimberti, G. G. Gallo, E. Selva and
L. F. Zerilli, J. Antibiot., 1996, 49, 150–154.
4 L. Vollbrecht, H. Steinmetz and G. Hofle, J. Antibiot., 2002,
55, 715–721.
5 I. Nickeleit, S. Zender, F. Sasse, R. Geﬀers, G. Brandes,
I. Soerensen, H. Steinmetz, S. Kubicka, T. Carlomagno,
D. Menche, I. Guetgemann, J. Buer, A. Gossler,
M. P. Manns, M. Kalesse, R. Frank and N. P. Malek, Cancer
Cell, 2008, 14, 23–35.
6 L. Buelow, I. Nickeleit, A.-K. Girbig, T. Brodmann,
A. Rentsch, U. Eggert, F. Sasse, H. Steinmetz, R. Frank,
T. Carlomagno, N. P. Malek and M. Kalesse, ChemMed-
Chem, 2010, 5, 832–836.
7 B. Nyfeler, D. Hoepfner, D. Palestrant, C. A. Kirby,
L. Whitehead, R. Yu, G. Deng, R. E. Caughlan, A. L. Woods,
A. K. Jones, S. W. Barnes, J. R. Walker, S. Gaulis, E. Hauy,
S. M. Brachmann, P. Krastel, C. Studer, R. Riedl,
D. Estoppey, T. Aust, N. R. Movva, Z. Wang, M. Salcius,
G. A. Michaud, G. McAllister, L. O. Murphy, J. A. Tallarico,
C. J. Wilson and C. R. Dean, PLoS One, 2012, 7, e42657.
8 P. Bielecki, P. Lukat, K. Huesecken, A. Doetsch,
A. H. Steinmetz, R. W. Hartmann, R. Mueller and
S. Haeussler, ChemBioChem, 2012, 13, 2339–2345.
9 E. A. Villar, D. Beglov, S. Chennamadhavuni, J. A. Porco Jr.,
D. Kozakov, S. Vajda and A. Whitty, Nat. Chem. Biol., 2014,
10, 723–731.
10 (a) S. V. Ley, A. Priour and C. Heusser, Org. Lett., 2002, 4,
711–714; (b) G. Blaser, J. M. Sanderson, A. S. Batsanov and
J. A. K. Howard, Tetrahedron Lett., 2008, 49, 2795–2798;
(c) R. J. M. Goss and P. L. A. Newill, Chem. Commun., 2006,
4924–4925.
11 J. Ma, W. Yin, H. Zhou, X. Liao and J. M. Cook, J. Org.
Chem., 2009, 74, 264–273.
12 K. Harada, Nature, 1963, 200, 1201.
13 W. Wu, Z. Li, G. Zhou and S. Jiang, Tetrahedron Lett., 2011,
52, 2488–2491.
Fig. 2 The eﬀects of argyrin A 20h and analogue 20g on the growth of
amoxicillin-resistant P. aeruginosa PAO1 in Muller–Hinton broth at 13 h.
Organic & Biomolecular Chemistry Communication






















































































14 R. H. Dave and B. D. Hosangadi, Tetrahedron, 1999, 55,
11295–11308.
15 A. Arasappan, S. Venkatraman, A. I. Padilla, W. L. Wu,
T. Meng, Y. Jin, J. Wong, A. Prongay, V. Girijavallabhan and
F. G. Njoroge, Tetrahedron Lett., 2007, 48, 6343–6347.
16 A. R. Katritzky, B. Pilarski and L. Urogdi, Synthesis, 1989,
949–950.
17 E. Vedejs and C. Kongkittingam, J. Org. Chem., 2001, 66,
7355–7364.
18 R. Baltzly and P. B. Russell, J. Am. Chem. Soc., 1953, 75,
5598–5602.
19 R. C. Bernotas and R. V. Cube, Synth. Commun., 1990, 20,
1209–1212.
20 M. Truong, F. Lecornue and A. Fadel, Tetrahedron: Asymme-
try, 2003, 14, 1063–1072.
21 D. Hazelard, A. Fadel and C. Girard, Tetrahedron: Asymme-
try, 2006, 17, 1457–1464.
22 G. Brieger and T. J. Nestrick, Chem. Rev., 1974, 74, 567–580.
23 S. Ram and L. D. Spicer, Tetrahedron Lett., 1987, 28, 515–
516.
24 J. Li, S. Wang, G. A. Crispino, K. Tenhuisen, A. Singh and
J. A. Grosso, Tetrahedron Lett., 2003, 44, 4041–4043.
25 P. J. Kocienski, Protecting groups, Georg Thieme Verlag,
New York, 2005.
26 S. D. Bull, S. G. Davies, G. Fenton, A. W. Mulvaney,
R. S. Prasad and A. D. Smith, J. Chem. Soc., Perkin Trans. 1,
2000, 3765–3774.
27 S. Kokinaki, L. Leondiadis and N. Ferderigos, Org. Lett.,
2005, 7, 1723–1724.
28 S. V. Ley and A. Priour, Eur. J. Org. Chem., 2002, 3995–4004.
Communication Organic & Biomolecular Chemistry
9768 | Org. Biomol. Chem., 2014, 12, 9764–9768 This journal is © The Royal Society of Chemistry 2014
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
2 
O
ct
ob
er
 2
01
4.
 D
ow
nl
oa
de
d 
on
 1
3/
10
/2
01
6 
13
:0
5:
23
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
